LifeSci Capital Reiterates Buy Rating on MANE
LifeSci Capital maintains its buy rating on MANE, setting a $135 price target, a 40.23% upside from the current price.
Key Points
- LifeSci Capital reiterated its buy rating on MANE with a $135 price target on June 16, 2026.
- LifeSci Capital's $135 price target implies 40.23% upside from Veradermics, Incorporated's ($MANE) current $96.27 share price.
- MANE shares are trading around $96.27, with several analysts maintaining a positive outlook.
- Institutional investors like Ameriprise Financial and Jennison Associates hold significant positions in MANE.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, LifeSci Capital reiterated its buy rating on MANE, setting a price target of $135. The shares are currently trading at about $96.27.
Other Institutional Activity in MANE
Ameriprise Financial Inc holds 514,035 shares of MANE, valued at approximately $32.46 million. Jennison Associates LLC has 141,781 shares, worth around $8.95 million. Similarly, Emerald Advisers, LLC controls 132,536 shares, valued at about $8.37 million, while Emerald Mutual Fund Advisers Trust holds 109,283 shares, valued at $6.90 million. Seven Grand Managers, LLC and Bamco Inc /NY/ have smaller stakes, with 74,750 and 59,668 shares, valued at $4.72 million and $3.77 million, respectively.
Analysts Set New Price Targets
On June 16, 2026, LifeSci Capital reiterated its buy rating on MANE with a $135 price target. Earlier, on June 2, 2026, Needham initiated coverage with a buy rating and a $136 target. Citigroup maintained its buy rating with a $135 target on May 18, 2026. Leerink Partners maintained a buy rating with a $90 target on April 22, 2026.
About MANE
MANE is involved in diverse sectors, focusing on providing innovative solutions across its industry. The company is committed to delivering high-quality products and services to its customers worldwide. As a dynamic player, MANE continues to expand its footprint in various markets, driven by a strong leadership team and a dedicated workforce.
Bottom Line
LifeSci Capital's reiteration of a buy rating with a $135 target reflects ongoing confidence in MANE's potential. Investors often track such analyst updates to gauge market sentiment. It's important to note that analyst ratings are forward-looking and may not reflect current market conditions.
Get Veradermics, Incorporated alerts
New 13F filings, insider trades, and analyst moves on $MANE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.